AAD

New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma

Retrieved on: 
Thursday, January 18, 2024

While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.

Key Points: 
  • While ART can benefit some patients, selecting patients based upon clinicopathologic factors alone can lead to overtreatment of certain patients who may not experience disease progression.
  • In the study, normalized medical claims data identified 22,917 Medicare-eligible SCC patients in the United States who received ART in the 12 months ending June 2022.
  • Results from the study indicate that using the DecisionDx-SCC test to guide decisions about ART could result in net Medicare healthcare savings of up to approximately $972 million annually.
  • This outcome is based on the distribution of DecisionDx-SCC test results reported in previous studies, with cost reductions attributed to avoiding ART in patients with a DecisionDx-SCC low-risk, Class 1 test result and low rates of disease progression.

AMERICAN ACADEMY OF DERMATOLOGY: START THE NEW YEAR OFF WITH A FRESH START (AND SKIN)

Retrieved on: 
Tuesday, January 9, 2024

ROSEMONT, Ill., Jan. 9, 2024 /PRNewswire/ -- With a rise in both public accessibility and visibility, cosmetic treatments are more popular than ever. Whether your New Year's resolution is to improve your health or to look and feel your best, the most important thing to remember is that your results depend largely on the skills and knowledge of the person performing your treatment.

Key Points: 
  • "There is no one-size-fits-all or 'cookie cutter' approach to combat the signs of aging because aging looks different on everyone.
  • On the flipside, there is no one cosmetic treatment to address all of these changes," said Lauren Fine, MD, FAAD, a board-certified dermatologist in Chicago.
  • While over-the-counter options are available, they may not be able to provide the results that a cosmetic procedure can deliver.
  • If you have specific cosmetic concerns or questions about a particular treatment, the best place to start is with a board-certified dermatologist.

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Tuesday, January 9, 2024

STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward.

Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board

Retrieved on: 
Tuesday, December 19, 2023

TAMPA, Fla., Dec. 19, 2023 /PRNewswire/ -- At the forefront of the Inhibitor Therapeutics, Inc. (OTCQB:INTI) pipeline is the use of Itraconazole to treat basal cell carcinomas in Basal Cell Carcinoma Nevus Syndrome (BCCNS) aka Gorlin Syndrome. This rare hereditary cancer syndrome is characterized by patients with hundreds to thousands of basal cell carcinomas. BCCNS is an orphan disease with approximately 11,000 patients in the USA. It is an autosomal dominant disorder that may affect every organ system. 

Key Points: 
  • Inhibitor believes that itraconazole has clinically meaningful effects on the BCCs, which led us to recruit a team of five experienced Mohs surgeons to form a Scientific Advisory Board (SAB) to critically review the outcomes of Inhibitor's phase 2b trial in BCCNS.
  • She is affiliated with the Gorlin Syndrome Alliance and is a member of their Medical and Scientific Advisory Committee.
  • She was a member of the Scientific Assembly Committee and Membership Committee for the American Academy of Dermatology (AAD) 2012-17.
  • She was appointed to the Board of Directors for the American Board of Dermatology for 2019-2027 and is a member and Chairman of the board question writing committee for dermatologic surgery.

Ad Astra Diagnostics receives 510(k) clearance of QScout™ hematology analyzer, the first to report measures of infection and severity at point-of-care

Retrieved on: 
Thursday, December 7, 2023

MORRISVILLE, N.C., Dec. 7, 2023 /PRNewswire/ -- Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Key Points: 
  • QScout™ is the first hematology platform designed for simple, fast operation at the point-of-care.
  • It provides lab-grade, patient-side results that caregivers use to screen for health conditions including infection, leukemia, and other blood-related cancers, allergies, and many more.
  • Elevated levels of IGs have been shown to differentiate sepsis earlier than commonly used measures like lactate and procalcitonin1.
  • Additionally, NLR is an increasingly important predictor of poor health outcomes that gained greater use during the pandemic.

FDA Implements AADA's iPLEDGE Recommendations

Retrieved on: 
Tuesday, December 5, 2023

WASHINGTON, Dec. 5, 2023 /PRNewswire/ -- The FDA agreed to require important American Academy of Dermatology's (AAD) recommended changes to the iPLEDGE program that will alleviate administrative burdens for dermatologists.

Key Points: 
  • "The FDA supported the AADA's critical recommendations that include allowing for continued use of at home and non-CLIA pregnancy tests."
  • In 2023, 300 AAD members sent about 600 messages to the FDA urging changes to iPLEDGE REMS Program.
  • These grassroots efforts, combined with AAD's strong advocacy led by its iPLEDGE Workgroup, including testifying during an FDA hearing in March, convinced the FDA to require modifications to the iPLEDGE REMS to minimize burdens on patients and dermatologists while maintaining the safe use of isotretinoin.
  • The AAD has been fighting for these changes since 2021, when the FDA transitioned to a new iPLEDGE platform that malfunctioned and disrupted treatment for many patients.

Ad Astra Diagnostics receives 510(k) clearance of QScout™ hematology analyzer, the first to report measures of infection and severity at point-of-care

Retrieved on: 
Thursday, November 16, 2023

MORRISVILLE, N.C., Nov. 16, 2023 /PRNewswire/ -- Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.

Key Points: 
  • QScout™ is the first hematology platform designed for simple, fast operation at the point-of-care.
  • It provides lab-grade, patient-side results to screen for health conditions including infection, leukemia and other blood-related cancers, allergies, and many more.
  • Additionally, NLR is an increasingly important predictor of poor health outcomes, which gained greater use during the pandemic.
  • Sepsis, the body's extreme response to infection, is a life-threatening medical emergency that happens when infection triggers a chain reaction throughout the body.

Congress must act to protect patients' health care access

Retrieved on: 
Thursday, November 2, 2023

WASHINGTON, Nov. 2, 2023 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) finalized cuts to the physician fee schedule for 2024, which will impact the ability of medical practices to cover expenses like equipment, rent, and nursing and office staff salaries. Put plainly, our ability to care for our patients is threatened, putting patients at risk of more hospitalizations for untreated illnesses and chronic conditions. 

Key Points: 
  • Put plainly, our ability to care for our patients is threatened, putting patients at risk of more hospitalizations for untreated illnesses and chronic conditions.
  • If these cuts are allowed to continue, access to their care is threatened.
  • The failure of Medicare physician payments to keep up with inflation is the greatest threat to maintaining seniors' access to care.
  • The AAD calls on Congress to stop these Medicare cuts before more patients will suffer.

FIVE UNSAFE SKIN CARE TRENDS TO AVOID

Retrieved on: 
Wednesday, November 1, 2023

ROSEMONT, Ill. , Nov. 1, 2023 /PRNewswire/ -- Social media platforms are rife with skin care advice from a variety of sources, which can make it difficult to know how to approach the recommendations you find online. In recognition of National Healthy Skin Month this November, board-certified dermatologists are spotlighting unsafe skin care trends that they see on social media and elsewhere to help you keep your skin looking its best.

Key Points: 
  • In recognition of National Healthy Skin Month this November, board-certified dermatologists are spotlighting unsafe skin care trends that they see on social media and elsewhere to help you keep your skin looking its best.
  • While self-tanner that you apply to your skin is a safe way to look tan, nasal tanning spray is not.
  • The sun exposure increases your risk of developing skin cancer and signs of premature skin aging like wrinkles and age spots.
  • Board-certified dermatologists have the expertise and training needed to perform cosmetic procedures and advise people on how to best care for and protect their hair, skin, and nails.

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

Retrieved on: 
Wednesday, October 11, 2023

These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.

Key Points: 
  • These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.
  • Opzelura is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
  • The overall prevalence of the condition is estimated to be approximately 2-3 million2, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo3.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 304.